Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zymogen granule protein 16 is a carbohydrate-binding lectin encoded by the ZG16 gene, predominantly expressed in secretory tissues such as the colon, endometrium, and spleen[2][5]. It serves as a linker between secretory proteins in the trans-Golgi network and the zymogen granule membrane, facilitating granule formation and proper protein trafficking[5][7]. ZG16 mediates defense against Gram-positive bacteria by supporting mucosal barrier integrity, and its downregulation is associated with colorectal cancer and other diseases affecting secretory and mucin-producing cells[2][3][5]. It features a jacalin-like lectin domain and a flexible C-terminal CXXC motif with redox activity, interacting with oxidases such as quiescin sulfhydryl oxidase 1 and protein disulfide isomerase[3]. Disruption of ZG16 impacts host defense, barrier function, and is implicated in several genetic and autoimmune diseases.
Not applicable (no approved drugs; theoretical mechanisms would involve modulating its carbohydrate binding, affecting protein trafficking, or enhancing anti-pathogenic defense in epithelial cells based on its molecular functions[1][3][5])
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zymogen granule protein 16 (ZG16).